Exenatide once weekly for smoking cessation: study protocol for a randomized clinical trial

• Published in: Medicine (Baltimore) Vol. 97; no. 2; p. e9567
• Main Authors: Yammine, Luba, Kosten, Thomas R., Cinciripini, Paul M., Green, Charles E., Meininger, Janet C., Minnix, Jennifer A., Newton, Thomas F.
• Format: Journal Article
• Language: English
• Published: United States The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved 01.01.2018; Wolters Kluwer Health
• Subjects: Administration, Cutaneous; Adolescent; Adult; Aged; Counseling; Craving - drug effects; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Exenatide; Glucagon-Like Peptide 1 - agonists; Humans; Middle Aged; Peptides - administration & dosage; Smoking - drug therapy; Smoking Cessation - methods; Study Protocol Clinical Trial; Substance Withdrawal Syndrome - drug therapy; Treatment Outcome; Venoms - administration & dosage; Young Adult
• ISSN: 0025-7974; 1536-5964; 1536-5964
• DOI: 10.1097/MD.0000000000009567

Cigarette smoking is the greatest preventable cause of morbidity and premature mortality in the United States. Approved pharmacological treatments for smoking cessation are marginally effective, underscoring the need for improved pharmacotherapies. A novel approach might use glucagon-like peptide-1 (GLP-1) agonists, which reduce alcohol and drug use in preclinical studies. GLP-1 is produced in the intestinal L-cells and in the hindbrain. The peptide maintains glucose homeostasis and reduces food intake. Several GLP-1 agonists are used clinically to treat type 2 diabetes and obesity, but none have been tested in humans to reduce smoking. We will examine whether extended-release exenatide reduces smoking, craving, and withdrawal symptoms, as well as cue-induced craving for cigarettes. We will enroll prediabetic and/or overweight treatment seeking smokers (n = 90) into a double-blind, placebo-controlled, randomized clinical trial. Participants will be randomized in a 1:1 ratio to receive exenatide or placebo. All participants will receive transdermal nicotine replacement therapy (NRT) and behavioral counseling. Abstinence from smoking (verified via expired CO level of ≤5 ppm), craving (Questionnaire of Smoking Urges score), and withdrawal symptoms (Wisconsin Scale of Withdrawal Symptoms score) will be assessed weekly during 6 weeks of treatment and at 1 and 4 weeks posttreatment. Cue-induced craving for cigarettes will be assessed at baseline and at 3 weeks of treatment following virtual reality exposure. We hypothesize that exenatide will increase the number of participants able to achieve complete smoking abstinence above that achieved via standard NRT and that exenatide will reduce craving and withdrawal symptoms, as well as cue-induced craving for cigarettes.